Top

Published in:

01-03-2019 | Leukemia | Original Article

Association of high levels of plasma OX40 with acute adult T-cell leukemia

Authors: Yuetsu Tanaka, Yoshiaki Takahashi, Reiko Tanaka, Takuya Miyagi, Mineki Saito, Takuya Fukushima

Published in: International Journal of Hematology | Issue 3/2019

Abstract

OX40, a member of the tumor necrosis factor receptor (TNFR) superfamily, co-stimulates activated T cells following interaction with its own ligand OX40L. Human T-cell leukemia virus type-1 (HTLV-1) is an etiological agent of adult T-cell leukemia (ATL). ATL cells are known to express cell surface OX40; however, the level of soluble OX40 (sOX40) in blood samples from ATL patients is unknown. Quantitative enzyme-linked immune-sorbent assay (ELISA) showed that sOX40 levels were significantly higher in plasma from acute ATL patients than those from asymptomatic HTLV-1 carriers and healthy donors, and correlated with sCD25 levels and HTLV-1 proviral loads in peripheral blood mononuclear cells (PBMCs). Fresh PBMCs from acute ATL patients showed a higher percentage of OX40-positive cells compared with those from carriers, and shed sOX40 into culture supernatants. Shedding of sOX40 was partially inhibited by a matrix metalloproteinase (MMP) inhibitor, GM6001. A fraction of sOX40 was capable of binding to OX40L. These results suggest that high levels of sOX40 are shed into blood from a large number of ATL cells in acute ATL patients. Thus, abnormally elevated plasma sOX40 levels may be useful as an additional diagnostic marker of acute ATL.

Available only for authorised users

Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor. EMBO J. 1990;9(4):1063–8.PubMedPubMedCentralCrossRef

Ishii N, Takahashi T, Soroosh P, Sugamura K. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol. 2010;105:63–98.PubMedCrossRef

Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57–78.PubMedPubMedCentralCrossRef

Tanaka Y, Inoi T, Tozawa H, Yamamoto N, Hinuma Y. A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). Int J Cancer. 1985;36(5):549–55.PubMedCrossRef

Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981;78(10):6476–80.PubMedCrossRef

Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15(11):e517-26.PubMedCrossRef

Miyoshi H, Ohshima K. Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan. Int J Hematol. 2018;107(4):420–7.PubMedCrossRef

Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159(8):3838–48.PubMed

Takasawa N, Ishii N, Higashimura N, Murata K, Tanaka Y, Nakamura M, et al. Expression of gp34 (OX40 ligand) and OX40 on human T cell clones. Jpn J Cancer Res. 2001;92(4):377–82.PubMedPubMedCentralCrossRef

10.

Pichler K, Kattan T, Gentzsch J, Kress AK, Taylor GP, Bangham CR, et al. Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients’ T cells by the viral Tax oncoprotein. Blood. 2008;111(9):4741–51.PubMedCrossRef

11.

Kress AK, Grassmann R, Fleckenstein B. Cell surface markers in HTLV-1 pathogenesis. Viruses. 2011;3(8):1439–59.PubMedPubMedCentralCrossRef

12.

Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 1996;183(5):2185–95.PubMedCrossRef

13.

Imura A, Hori T, Imada K, Kawamata S, Tanaka Y, Imamura S, et al. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Blood. 1997;89(8):2951–8.PubMedCrossRef

14.

Hintzen RQ, de Jong R, Hack CE, Chamuleau M, de Vries EF, ten Berge IJ, et al. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J Immunol. 1991;147(1):29–35.PubMed

15.

Del Prete G, Maggi E, Pizzolo G, Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today. 1995;16(2):76–80.PubMedCrossRef

16.

Porteu F, Hieblot C. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J Biol Chem. 1994;269(4):2834–40.PubMed

17.

Takemoto S, Iwanaga M, Sagara Y, Watanabe T. Plasma soluble CD30 as a possible marker of adult T-cell leukemia in HTLV-1 carriers: a nested case-control study. Asian Pac J Cancer Prev: APJCP. 2015;16(18):8253–8.PubMedCrossRef

18.

Compaan DM, Hymowitz SG. The crystal structure of the costimulatory OX40-OX40L complex. Structure. 2006;14(8):1321–30.PubMedCrossRef

19.

Kondo K, Okuma K, Tanaka R, Zhang LF, Kodama A, Takahashi Y, et al. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells. Hum Immunol. 2007;68(7):563–71.PubMedCrossRef

20.

Tozawa H, Andoh S, Takayama Y, Tanaka Y, Lee B, Nakamura H, et al. Species-dependent antigenicity of the 34-kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human T-cell leukemia virus type-I (HTLV-I) and simian T-cell leukemia virus (STLV-I). Int J Cancer. 1988;41(2):231–8.PubMedCrossRef

21.

Saito M, Tanaka R, Arishima S, Matsuzaki T, Ishihara S, Tokashiki T, et al. Increased expression of OX40 is associated with progressive disease in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology. 2013;10:51.PubMedPubMedCentralCrossRef

22.

Tanaka Y, Inoi T, Tozawa H, Sugamura K, Hinuma Y. New monoclonal antibodies that define multiple epitopes and a human-specific marker on the interleukin 2 receptor molecules of primates. Microbiol Immunol. 1986;30(4):373–88.PubMedCrossRef

23.

Tanaka R, Takahashi Y, Kodama A, Saito M, Ansari AA, Tanaka Y. Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of beta-chemokines. AIDS Res Hum Retroviruses. 2010;26(10):1147–54.PubMedCrossRef

24.

Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79(3):428–37.PubMedCrossRef

25.

Kunihiro M, Fujii H, Miyagi T, Takahashi Y, Tanaka R, Fukushima T, et al. Heat shock enhances the expression of the human T cell leukemia virus type-I (HTLV-I) trans-activator (tax) antigen in human HTLV-I infected primary and cultured T cells. Viruses. 2016;8(7).

26.

Takahashi Y, Tanaka R, Yamamoto N, Tanaka Y. Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production. AIDS Res Hum Retroviruses. 2008;24(3):423–35.PubMedCrossRef

27.

Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4(6):586–93.PubMedCrossRef

28.

Tanaka R, Yoshida A, Murakami T, Baba E, Lichtenfeld J, Omori T, et al. Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection. J Virol. 2001;75(23):11534–43.PubMedPubMedCentralCrossRef

29.

Hayashida K, Bartlett AH, Chen Y, Park PW. Molecular and cellular mechanisms of ectodomain shedding. Anat Rec. (Hoboken, NJ: 2007). 2010;293(6):925–937CrossRef

30.

Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer cell. 2012;21(1):121–35.PubMedCrossRef

31.

Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, Nakano K, et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood. 2016;127(14):1790–802.PubMedCrossRef

32.

Ma BY, Mikolajczak SA, Danesh A, Hosiawa KA, Cameron CM, Takaori-Kondo A, et al. The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells. Blood. 2005;106(6):2002–10.PubMedCrossRef

33.

Michel J, Langstein J, Hofstadter F, Schwarz H. A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol. 1998;28(1):290–5.PubMedCrossRef

34.

Mori N, Sato H, Hayashibara T, Senba M, Hayashi T, Yamada Y, et al. Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood. 2002;99(4):1341–9.PubMedCrossRef

35.

Nakachi S, Nakazato T, Ishikawa C, Kimura R, Mann DA, Senba M, et al. Human T-cell leukemia virus type 1 tax transactivates the matrix metalloproteinase 7 gene via JunD/AP-1 signaling. Biochim Biophys Acta. 2011;1813(5):731–41.PubMedCrossRef

36.

Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229(1):173–91.PubMedPubMedCentralCrossRef

37.

Tashiro T, Yamasaki T, Nagai H, Kikuchi H, Nasu M. Immunological studies on opportunistic infection and the development of adult T-cell leukemia. Internal Med (Tokyo Japan). 1992;31(9):1132–6.CrossRef

38.

Tanaka T, Sekioka T, Usui M, Imashuku S. Opportunistic infections in patients with HTLV-1 infection. Case Repo Hematol. 2015;2015:943867.

Title: Association of high levels of plasma OX40 with acute adult T-cell leukemia
Authors: Yuetsu Tanaka
Yoshiaki Takahashi
Reiko Tanaka
Takuya Miyagi
Mineki Saito
Takuya Fukushima
Publication date: 01-03-2019
Publisher: Springer Japan
Keyword: Leukemia
Published in: International Journal of Hematology / Issue 3/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-018-02580-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Tuberculous lymphadenitis mimicking Castleman disease-like histological features

Clinical features of dyskeratosis congenita in mainland China: case reports and literature review

Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin’s lymphoma after allogeneic hematopoietic stem cell transplantation

A case of pancytopenia and hypercellular bone marrow: when family history can suggest the diagnosis

Correction to: Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer